Biogen’s CEO Chris Vibacher said ‘a new Biogen’ is emerging following the end of its multiple sclerosis treatments heyday.

Eli Lilly’s strong quarterly results were overshadowed by CVS’s decision to favour Novo Nordisk’s Wegovy over Zepbound.

The London Cancer Hub has been identified as a key district for ‘frontier innovation’ by London Mayor Sadiq Khan.

Dimerix and Amicus Therapeutics have signed an agreement for the US commercialisation of the former’s Phase III drug ...

GSK said it remains confident it can absorb the financial impact of potential US tariffs as it posted a 4% rise in Q1 2025 ...

Novartis has signed an agreement to acquire US-based Regulus Therapeutics and its oligonucleotide, farabursen.

J&J's Imaavy (nipocalimab-aahu) has received US Food and Drug Administration (FDA) approval for treating generalised ...

The slowdown in IPOs following tariff-associated turbulence and FDA reorganisation will soon pass, say industry investors.

Data from the NERO study investigating Zejula in mesothelioma was presented at the American Association of Cancer Research ...

Biopharmaceutical drug company venture financing witnessed a downturn in Q1 2025 —a 20.2% decline from the $8.1bn raised in ...

While pharma manufacturing deals in the US increased, large cuts to research and regulatory agencies increased concerns for the sector.

Boehringer Ingelheim, along with the University of Oxford, UK, and Cumulus Neuroscience, has launched a study for BPD.